Target Name: GUCY1B2
NCBI ID: G2974
Other Name(s): Guanylate cyclase 1 soluble subunit beta 2 (pseudogene) | guanylate cyclase 1 soluble subunit beta 2 (pseudogene) | GCYB2_HUMAN | Guanylate cyclase 1, soluble, beta 2 | Guanylate cyclase soluble subunit beta-2 | GC-SB2 | Soluble guanylate cyclase beta 2 | GCS-beta-2

GUCY1B2: A Potential Drug Target and Biomarker

Guanylate cyclase 1 (GCY1) is a gene that encodes for the enzyme soluble subunit beta 2 (GCY1B2). GCY1B2 is a key enzyme in the intracellular signaling pathway known as the G-protein-coupled receptor (GPCR) signaling pathway. This pathway plays a crucial role in regulating various cellular processes, including but not limited to cell survival, proliferation, and signaling. GUCY1B2 is a pseudogene, which means that it was introduced into the genome but does not have the ability to produce functional proteins.

GUCY1B2 has been identified as a potential drug target due to its involvement in several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its involvement in these diseases has led to the development of new therapeutic strategies, including but not limited to inhibition of GCY1B2 activity.

One of the main challenges in studying GCY1B2 is its expression and function, as it is a pseudogene and has not been studied extensively. However, research has shown that GCY1B2 is involved in several cellular processes, including but not limited to cell adhesion, migration, and survival.

Studies have also shown that GCY1B2 is involved in several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. For example, GCY1B2 has been shown to be involved in the development and progression of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease.

In addition, GCY1B2 has also been shown to be involved in the development and progression of autoimmune disorders, such as rheumatoid arthritis and multiple sclerosis. These diseases are characterized by the production of antibodies that target the body's own tissues and can cause significant suffering and disability.

GUCY1B2 has also been shown to be involved in the regulation of cellular processes that are important for cancer progression, including the angiogenesis, cell proliferation, and survival. This suggests that GCY1B2 may play a role in the development and progression of cancer.

In conclusion, GUCY1B2 is a gene that has been identified as a potential drug target due to its involvement in several diseases. Further research is needed to fully understand its function and the therapeutic potential of inhibiting GCY1B2 activity. Understanding the role of GCY1B2 in these diseases could lead to the development of new therapeutic strategies that can provide significant relief from the suffering and disability caused by these conditions.

Protein Name: Guanylate Cyclase 1 Soluble Subunit Beta 2 (pseudogene)

More Common Targets

GUCY2C | GUCY2D | GUCY2EP | GUCY2F | GUCY2GP | GUF1 | GUK1 | GULOP | GULP1 | GUSB | GUSBP1 | GUSBP11 | GUSBP12 | GUSBP14 | GUSBP15 | GUSBP17 | GUSBP2 | GUSBP3 | GUSBP4 | GUSBP5 | GUSBP8 | GVINP1 | GVQW3 | GXYLT1 | GXYLT1P3 | GXYLT1P4 | GXYLT1P6 | GXYLT2 | GYG1 | GYG2 | GYPA | GYPB | GYPC | GYPE | GYS1 | GYS2 | GZF1 | GZMA | GZMB | GZMH | GZMK | GZMM | H1-0 | H1-1 | H1-10 | H1-10-AS1 | H1-2 | H1-3 | H1-4 | H1-5 | H1-6 | H1-7 | H1-8 | H1-9P | H19 | H19-ICR | H2AB1 | H2AB2 | H2AB3 | H2AC1 | H2AC11 | H2AC12 | H2AC13 | H2AC14 | H2AC15 | H2AC16 | H2AC17 | H2AC18 | H2AC20 | H2AC21 | H2AC25 | H2AC3P | H2AC4 | H2AC6 | H2AC7 | H2AJ | H2AP | H2AX | H2AZ1 | H2AZ1-DT | H2AZ2 | H2AZ2-DT | H2AZP2 | H2BC1 | H2BC10 | H2BC11 | H2BC12 | H2BC12L | H2BC13 | H2BC14 | H2BC15 | H2BC17 | H2BC18 | H2BC20P | H2BC21 | H2BC26 | H2BC27P | H2BC3 | H2BC4 | H2BC5